ArticleBMC public health2025

A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective.

Nirma Khatri Vadlamudi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.